Liminatus Pharma Inc (LIMN) Stock Analysis
Verdict: AVOID
Critical liquidity crisis and negative equity make this a 'dead man walking' trade, where survival depends entirely on dilutive financing.
Investment score: 12/100
Analysis as of
Is Liminatus Pharma Inc stock worth reviewing? AI model thesis
LIMN is a pre-revenue micro-cap biotech with critical liquidity issues and a single-employee structure. Despite a recent technical surge, the fundamental outlook is dominated by insolvency risk and a lack of clinical catalysts to offset the $10M annual cash burn.
7-factor investment score
- Valuation: 5/100 (weight 20%)
- Financial Health: 0/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Liminatus Pharma Inc opportunities and risks
What speaks for LIMN
- Technical Mean Reversion
What speaks against LIMN
- Imminent Dilutive Financing
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LIMN | n/a | 0.0x | n/a | 0.0% | 0.0% | -119.1% |
| BIVI | n/a | 0.0x | 441459.6x | 0.0% | 0.0% | -161692418.9% |
| INAB | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -129.0% |
| TOVX | n/a | 35.2x | n/a | 92.0% | -3872.7% | -117.2% |
| LSTA | n/a | 102.9x | 0.0x | 95.0% | -14621.0% | -119.8% |
| LNAI | n/a | 485.0x | n/a | -360.7% | -612568.1% | -51.8% |
| Peer median | n/a | 35.2x | 0.0x | 0.0% | -3872.7% | -119.8% |
Frequently asked questions about Liminatus Pharma Inc (LIMN)
Is LIMN stock a good investment?
The cached TradeMates AI model rates Liminatus Pharma Inc as AVOID with an investment score of 12/100. LIMN is a pre-revenue micro-cap biotech with critical liquidity issues and a single-employee structure. Despite a recent technical surge, the fundamental outlook is dominated by insolvency risk and a lack of clinical catalysts to offset the $10M annual cash burn. This is algorithmic model output, not personal investment advice.
Is LIMN stock a buy?
The TradeMates model verdict for LIMN is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.